| State-of-the-art strategies for targeting the DNA damage response in cancer PG Pilié, C Tang, GB Mills, TA Yap Nature reviews Clinical oncology 16 (2), 81-104, 2019 | 895 | 2019 |
| High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, ... Annals of Oncology 32 (5), 661-672, 2021 | 702 | 2021 |
| PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers PG Pilié, CM Gay, LA Byers, MJ O'Connor, TA Yap Clinical Cancer Research 25 (13), 3759-3771, 2019 | 305 | 2019 |
| Development of PARP and immune-checkpoint inhibitor combinations RA Stewart, PG Pilié, TA Yap Cancer research 78 (24), 6717-6725, 2018 | 189 | 2018 |
| PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma XD Liu, W Kong, CB Peterson, DJ McGrail, A Hoang, X Zhang, T Lam, ... Nature communications 11 (1), 2135, 2020 | 143 | 2020 |
| Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ... Journal of Clinical Oncology 41 (18), 3339-3351, 2023 | 128 | 2023 |
| Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, YY Evan, ... The Lancet Oncology 23 (3), 362-373, 2022 | 127 | 2022 |
| Comprehensive molecular characterization identifies distinct genomic and immune hallmarks of renal medullary carcinoma P Msaouel, GG Malouf, X Su, H Yao, DN Tripathi, M Soeung, J Gao, ... Cancer Cell 37 (5), 720-734. e13, 2020 | 88 | 2020 |
| Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial E Jonasch, IE McCutcheon, DS Gombos, K Ahrar, ND Perrier, D Liu, ... The Lancet Oncology 19 (10), 1351-1359, 2018 | 88 | 2018 |
| ATR inhibition induces CDK1–SPOP signaling and enhances anti–PD-L1 cytotoxicity in prostate cancer Z Tang, PG Pilié, C Geng, GC Manyam, G Yang, S Park, D Wang, S Peng, ... Clinical Cancer Research 27 (17), 4898-4909, 2021 | 76 | 2021 |
| Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016 AO Elmehrath, AM Afifi, MJ Al-Husseini, AM Saad, N Wilson, KS Shohdy, ... JAMA Network Open 4 (8), e2119568-e2119568, 2021 | 65 | 2021 |
| Morphologically Normal-Appearing Mammary Epithelial Cells Obtained from High-Risk Women Exhibit Methylation Silencing of INK4a/ARF GR Bean, AD Bryson, PG Pilie, V Goldenberg, JC Baker Jr, C Ibarra, ... Clinical cancer research 13 (22), 6834-6841, 2007 | 62 | 2007 |
| Germline genetic variants in men with prostate cancer and one or more additional cancers PG Pilié, AM Johnson, KL Hanson, ME Dayno, AL Kapron, EM Stoffel, ... Cancer 123 (20), 3925-3932, 2017 | 60 | 2017 |
| CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis SN Vasilatos, G Broadwater, WT Barry, JC Baker Jr, S Lem, EC Dietze, ... Cancer Epidemiology Biomarkers & Prevention 18 (3), 901-914, 2009 | 60 | 2009 |
| Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers B Garmezy, J Gheeya, HY Lin, Y Huang, T Kim, X Jiang, KZ Thein, ... JCO Precision Oncology 6, e2100267, 2022 | 51 | 2022 |
| Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial C Tang, AD Sherry, C Haymaker, T Bathala, S Liu, B Fellman, L Cohen, ... JAMA oncology 9 (6), 825-834, 2023 | 47 | 2023 |
| Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer M Bowie, P Pilie, J Wulfkuhle, S Lem, A Hoffman, S Desai, E Petricoin, ... World Journal of Clinical Oncology 6 (6), 299, 2015 | 45 | 2015 |
| Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes P Pilie, WA Werbel, J Riddell IV, X Shu, D Schaubel, KS Gregg Transplant Infectious Disease 17 (4), 551-557, 2015 | 43 | 2015 |
| PARP and CDK4/6 inhibitor combination therapy induces apoptosis and suppresses neuroendocrine differentiation in prostate cancer C Wu, S Peng, PG Pilié, C Geng, S Park, GC Manyam, Y Lu, G Yang, ... Molecular cancer therapeutics 20 (9), 1680-1691, 2021 | 29 | 2021 |
| Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways C Ibarra-Drendall, MM Troch, WT Barry, G Broadwater, EF Petricoin, ... Breast cancer research and treatment 132, 487-498, 2012 | 29 | 2012 |
